Merck in Talks to Buy Biotech Revolution Medicines, FT Says

Merck & Co. is in talks to acquire the cancer-focused biotech company Revolution Medicines Inc., according to a report in the Financial Times.

The article comes one day after the Wall Street Journal reported that AbbVie Inc. was near a deal to buy Revolution. AbbVie said that story was inaccurate.